Loading…

Polymorphisms in innate immunity genes and patients response to dendritic cell-based HIV immuno-treatment

Abstract Dendritic cells (DCs)-based vaccine was demonstrated to increase HIV specific cellular immune response; however, in some HIV-infected patients, the response to the vaccine resulted to be not effective. In order to understand if the outcome of the vaccination may be influenced by the host�...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2010-03, Vol.28 (10), p.2201-2206
Main Authors: Segat, Ludovica, Brandão, Lucas A.C, Guimarães, Rafael L, Pontillo, Alessandra, Athanasakis, Emmanouil, de Oliveira, Rafael Martins, Arraes, Luiz C, de Lima Filho, Josè Luiz, Crovella, Sergio
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Dendritic cells (DCs)-based vaccine was demonstrated to increase HIV specific cellular immune response; however, in some HIV-infected patients, the response to the vaccine resulted to be not effective. In order to understand if the outcome of the vaccination may be influenced by the host's genome and natural immunity, we studied the innate immune genome of HIV-infected patients previously vaccinated with DCs. We identified 15 SNPs potentially associated with the response to the immuno-treatment and two SNPs significantly associated with the modulation of the response to the DC vaccine: MBL2 rs10824792 and NOS1 rs693534. These two SNPs were also studied in different ethnic groups (Brazilians, African and Caucasian) of HIV-infected, exposed uninfected and unexposed uninfected subjects. The HIV positive Caucasian patients were also characterized by different disease progressions. Our findings suggest that, independently and/or in addition to other variables, the host's genome could significantly contribute to the modulation of the response to the DC vaccine.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2009.12.056